Cytotherapy · 2020
International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Börger Verena, Weiss Daniel J, Anderson Johnathon D, Borràs Francesc E, Bussolati Benedetta, Carter David R F, Dominici Massimo, Falcón-Pérez Juan M, Gimona Mario, Hill Andrew F, Hoffman Andrew M, de Kleijn Dominique, Levine Bruce L, Lim Rebecca, Lötvall Jan, Mitsialis S Alex, Monguió-Tortajada Marta, Muraca Maurizio, Nieuwland Rienk, Nowocin Anna, O'Driscoll Lorraine, Ortiz Luis A, Phinney Donald G, Reischl Ilona, Rohde Eva, Sanzenbacher Ralf, Théry Clotilde, Toh Wei Seong, Witwer Kenneth W, Lim Sai Kiang, Giebel Bernd
Аннотация
The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.